MCID: MGR001
MIFTS: 46

Migraine Without Aura

Categories: Neuronal diseases

Aliases & Classifications for Migraine Without Aura

MalaCards integrated aliases for Migraine Without Aura:

Name: Migraine Without Aura 12 44 15
Common Migraine 12 55 73

Classifications:



External Ids:

Disease Ontology 12 DOID:12783
ICD10 33 G43.0 G43.009
ICD9CM 35 346.1
MeSH 44 D020326
NCIt 50 C117004
UMLS 73 C0338480

Summaries for Migraine Without Aura

Disease Ontology : 12 A migraine that is characterized by migraine headaches that are not accompanied by an aura.

MalaCards based summary : Migraine Without Aura, also known as common migraine, is related to headache and alexithymia. An important gene associated with Migraine Without Aura is MGR4 (Migraine, Susceptibility To, 4), and among its related pathways/superpathways are Circadian entrainment and Beta-Adrenergic Signaling. The drugs Milnacipran and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, pituitary and bone, and related phenotypes are behavior/neurological and integument

Related Diseases for Migraine Without Aura

Diseases related to Migraine Without Aura via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 88)
# Related Disease Score Top Affiliating Genes
1 headache 30.2 ATP1A2 CACNA1A SCN1A
2 alexithymia 29.8 DRD2 HTR1A SLC6A4
3 migraine with aura 27.8 ATP1A2 CACNA1A DRD2 KCNK18 MTHFR SCN1A
4 migraine with or without aura 1 27.0 ATP1A2 CACNA1A DRD2 DRD3 DRD4 HTR1A
5 migraine without aura 4 12.3
6 migraine, familial hemiplegic, 3 11.1
7 migraine with or without aura 13 11.1
8 polysubstance abuse 10.7 DRD2 DRD3
9 tardive dyskinesia 10.7 DRD2 DRD3
10 heroin dependence 10.6 DRD2 DRD4
11 delusional disorder 10.5 DRD2 DRD3 DRD4
12 impulse control disorder 10.5 DRD2 DRD3 DRD4
13 obsessive-compulsive personality disorder 10.4 DRD3 SLC6A4
14 alcohol-induced mental disorder 10.4 DRD2 SLC6A4
15 tic disorder 10.4 DRD2 DRD4
16 torticollis 10.4 CACNA1A DRD2
17 alcoholic psychosis 10.4 DRD2 SLC6A4
18 drug-induced mental disorder 10.3 DRD2 HTR1A
19 galactorrhea 10.3 DRD2 PRL
20 drug psychosis 10.3 DRD2 HTR1A
21 schizophreniform disorder 10.3 DRD2 PRL
22 prolactin producing pituitary tumor 10.3 DRD2 PRL
23 neuroleptic malignant syndrome 10.3 DRD2 HTR1A
24 orofacial cleft 10.2 DRD2 DRD4 MTHFR
25 cerebritis 10.2
26 psychosexual disorder 10.2 HTR1A SLC6A4
27 functioning pituitary adenoma 10.2 DRD2 PRL
28 oppositional defiant disorder 10.2 DRD2 DRD4 SLC6A4
29 opiate dependence 10.2 DRD2 DRD3 SLC6A4
30 cocaine dependence 10.1 DRD2 DRD3 SLC6A4
31 phobic disorder 10.1 HTR1A SLC6A4
32 drug dependence 10.1 DRD2 DRD3 SLC6A4
33 conduct disorder 10.1 DRD2 DRD4 SLC6A4
34 kleptomania 10.1 HTR1A SLC6A4
35 restless legs syndrome 10.1 CACNA1A DRD2 DRD3
36 premature ejaculation 10.1 HTR1A SLC6A4
37 peripartum cardiomyopathy 10.1 DRD2 PRL
38 bruxism 10.1 DRD2 SLC6A4
39 endometriosis 10.0
40 neuronitis 10.0
41 cluster headache 10.0
42 depression 10.0
43 periodic limb movement disorder 10.0 DRD2 HTR1A SLC6A4
44 generalized anxiety disorder 9.9 DRD2 HTR1A SLC6A4
45 neurofibromatosis, type i 9.9
46 aging 9.9
47 helicobacter pylori infection 9.9
48 fibrous dysplasia 9.9
49 pertussis 9.9
50 parametritis 9.9

Comorbidity relations with Migraine Without Aura via Phenotypic Disease Network (PDN):


Hypertension, Essential

Graphical network of the top 20 diseases related to Migraine Without Aura:



Diseases related to Migraine Without Aura

Symptoms & Phenotypes for Migraine Without Aura

MGI Mouse Phenotypes related to Migraine Without Aura:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.81 DRD3 DRD4 HTR1A PRL SCN1A SLC6A4
2 integument MP:0010771 9.5 ASTN2 ATP1A2 CACNA1A DRD2 MTHFR PRL
3 nervous system MP:0003631 9.36 ATP1A2 CACNA1A DRD2 DRD3 DRD4 HTR1A

Drugs & Therapeutics for Migraine Without Aura

Drugs for Migraine Without Aura (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 151)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
4
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
5
Almotriptan Approved, Investigational Phase 4 154323-57-6, 181183-52-8 123606
6
Topiramate Approved Phase 4,Phase 3,Phase 2 97240-79-4 5284627
7
Diphenhydramine Approved, Investigational Phase 4,Phase 3 147-24-0, 58-73-1 3100
8
Haloperidol Approved Phase 4 52-86-8 3559
9
Histamine Approved, Investigational Phase 4,Phase 3,Not Applicable 75614-87-8, 51-45-6 774
10
Promethazine Approved, Investigational Phase 4,Phase 3 60-87-7 4927
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
12 Adrenergic Agents Phase 4,Phase 2,Phase 3
13 Antidepressive Agents Phase 4
14 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Neurotransmitter Uptake Inhibitors Phase 4
16 Psychotropic Drugs Phase 4,Phase 2
17 Serotonin Agents Phase 4,Phase 3,Not Applicable
18 Serotonin Uptake Inhibitors Phase 4
19 Analgesics Phase 4,Phase 3,Phase 2,Not Applicable
20 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Not Applicable
21 Antiemetics Phase 4,Phase 3,Phase 1,Phase 2
22 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
23 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Not Applicable
24 Antirheumatic Agents Phase 4,Phase 3,Not Applicable
25 Autonomic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
26 Cyclooxygenase Inhibitors Phase 4,Phase 3,Not Applicable
27 Dopamine Agents Phase 4
28 Dopamine Antagonists Phase 4
29 Dopamine D2 Receptor Antagonists Phase 4
30 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
31 Ketorolac Tromethamine Phase 4
32 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Anticonvulsants Phase 4,Phase 3,Phase 2
34 Anti-Obesity Agents Phase 4,Phase 3,Phase 2
35 Neuroprotective Agents Phase 4,Phase 3,Phase 2,Not Applicable
36 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
37 Anesthetics Phase 4,Phase 3,Phase 1,Phase 2
38 Anesthetics, Local Phase 4,Phase 3,Phase 1,Phase 2
39 Anti-Allergic Agents Phase 4,Phase 3
40 Antipruritics Phase 4,Phase 3
41 Antipsychotic Agents Phase 4
42 Central Nervous System Depressants Phase 4,Phase 3,Phase 1,Phase 2
43 decanoic acid Phase 4
44 Dermatologic Agents Phase 4,Phase 3
45 Haloperidol decanoate Phase 4
46 Histamine Antagonists Phase 4,Phase 3,Not Applicable
47 Histamine H1 Antagonists Phase 4,Phase 3,Not Applicable
48
Histamine Phosphate Phase 4,Phase 3,Not Applicable 51-74-1 65513
49 Hypnotics and Sedatives Phase 4,Phase 3
50 Tranquilizing Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 78)
# Name Status NCT ID Phase Drugs
1 Preventive Treatment of Episodic and Chronic Migraine Unknown status NCT01319825 Phase 4 milnacipran
2 Intravenous Ketorolac and Metoclopramide for Pediatric Migraine in the Emergency Department Completed NCT01596166 Phase 4 Ketorolac Tromethamine;Metoclopramide
3 Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine Completed NCT00210496 Phase 4 topiramate; almotriptan malate
4 Evaluation of the Effectiveness of Topiramate in Preventing the Transformation From Episodic Migraine to Chronic Daily Headache. Completed NCT00212810 Phase 4 Topiramate
5 Haldol/Diphenhydramine Versus Metoclopramide/Diphenhydramine for Treatment of Acute Headache in the Emergency Department: A Randomized Controlled Trial Completed NCT02098499 Phase 4 Haloperidol;Metoclopramide 10mg;Diphenhydramine
6 Intravenous Metoclopramide in the Acute Treatment of Migraine: A Double-blind, Randomized, Placebo-controlled Trial Completed NCT02314351 Phase 4 Metoclopramide 10 mg;Placebo;Fentanyl
7 Acupuncture for Migraine Prophylaxis Unknown status NCT01687660 Phase 2, Phase 3
8 Dysport® In Migraine Without Aura Prophylaxis : DIMWAP Study Completed NCT00258609 Phase 3 Botulinum Toxin type A (Dysport ® ) IM/SC 6-sites pericranial injection
9 Eletriptan Provides Consistent Migraine Relief: Results Of A Within-Patient Multiple-Dose Study Completed NCT01859481 Phase 3 Placebo;Eletriptan HBr 40 mg;Eletriptan HBr 80 mg
10 Efficacy and Safety of Oral Sumatriptan Plus Oral Promethazine in Migraine Treatment Completed NCT01814189 Phase 3 Sumatriptan+Promethazine (SPr)
11 Is Chiropractic Spinal Manipulative Therapy an Efficient Treatment Option for Migraine Completed NCT01741714 Phase 3
12 Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine Completed NCT00334178 Phase 3 Laxymig ER (drug)
13 Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache Completed NCT00471952 Phase 3 Maxalt 10mg MLT plus Caffeine 75mg;Maxalt 10mg MLT plus Placebo;Placebo + Placebo
14 TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1) Completed NCT00387881 Phase 3 sumatriptan succinate / naproxen sodium;Placebo
15 Candesartan Versus Propranolol for Migraine Prevention Completed NCT00884663 Phase 2, Phase 3 Candesartan;propranolol;placebo
16 A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine Completed NCT00236509 Phase 3 topiramate
17 A Study of the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prevention of Migraine Completed NCT00236561 Phase 3 topiramate, propranolol
18 A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine Completed NCT00231595 Phase 3 topiramate
19 Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines Completed NCT00122278 Phase 3 dexamethasone 10mg IV
20 Oral ALLOD-2 vs. Its Components & vs. Placebo in the Acute Treatment of Migraine (ANODYNE-1) Completed NCT03061734 Phase 2, Phase 3 ALLOD-2;ALLOD-2H;Component A (regular dose);Component B;Placebo
21 Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention Completed NCT02456740 Phase 3 Erenumab;Placebo
22 Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention Completed NCT02483585 Phase 3 Erenumab;Placebo
23 Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine Unknown status NCT00285402 Phase 2 AST-726 Low dose;AST-726 High dose;AST-726 Placebo
24 Study of the Safety and Effectiveness of NXN-188 for the Treatment of Migraine Headache Without Aura Completed NCT00959751 Phase 2 NXN-188;Placebo
25 Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache Completed NCT00534560 Phase 2 Tonabersat;Tonabersat;Placebo
26 Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache Completed NCT00311662 Phase 2 Tonabersat;Placebo
27 Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache Completed NCT00123201 Phase 2 Dronabinol MDI
28 Botox Injection in Treatment of Chronic Migraine Completed NCT02259075 Phase 1, Phase 2 Botulinum Toxin Type A
29 Continuous Treatment Study of Topiramate in Migraine Participants Completed NCT01799590 Phase 2 Topiramate
30 A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention Completed NCT02066415 Phase 2 Placebo
31 A Dose-Finding Study of Topiramate (JNS019) in Participants With Migraine Completed NCT01081795 Phase 2 Topiramate;Placebo
32 A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention. Completed NCT02174861 Phase 2 Erenumab
33 Efficacy and Safety Study of E2007 in Migraine Prophylaxis Completed NCT00154063 Phase 2 E2007
34 Can DFN-15 Terminate Migraine With Allodynia? Recruiting NCT03472378 Phase 2 DFN-15
35 Treatment of Chronic Migraine Headaches. Recruiting NCT03220113 Phase 1, Phase 2
36 A Phase 2 Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention Active, not recruiting NCT01952574 Phase 2 Erenumab;Placebo
37 A Study of a Melatonin Receptor Agonist to Prevent Migraine Terminated NCT00739024 Phase 2 Ramelteon;Placebo
38 MIBRAIN - Migraine and the Brain: Consequences, Causes, and Vascular Interaction Unknown status NCT01803984
39 Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI Unknown status NCT02202486
40 Cortical Reorganisation in Patients With Primary Headache Disorders Unknown status NCT00263991
41 A TMU/NIH Integrated Research Project Translation of Basic Research to Clinical Diagnosis and Treatment of Mild Traumatic Brain Injury (mTBI) Unknown status NCT01266356
42 Inflammatory Markers Identification in Migraine Patients Unknown status NCT01618201
43 Identification of Inflammatory Markers in Migraine Patients Unknown status NCT00969995
44 Functional MRI (fMRI) in CGRP Induced Migraine Completed NCT00363532 Not Applicable infusion of calcitonin gene related peptide (CGRP)
45 Effect of PACAP38/VIP on Migraineurs Measured by Magnetic Resonance Completed NCT01471990 Not Applicable Pituitary Adenylate Cyclase-Activating Polypeptide-38;Vasoactive Intestinal Peptide
46 Investigation of Serotonin Receptor Binding in the Migraine Brain Using Positron Emission Tomography Completed NCT02309606
47 PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load Completed NCT02158221 Not Applicable PACAP
48 CGRP Induced Migraine Attacks in Patients With High and Low Genetic Load Completed NCT01924052 Not Applicable CGRP
49 The Effect of Histamine H1 Receptor Antagonist, Clemastin, on PACAP38 Induced Headache in Migraine Patients Completed NCT02364453 Not Applicable PACAP38
50 PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow Completed NCT00380263 Not Applicable PACAP38

Search NIH Clinical Center for Migraine Without Aura

Cochrane evidence based reviews: migraine without aura

Genetic Tests for Migraine Without Aura

Anatomical Context for Migraine Without Aura

MalaCards organs/tissues related to Migraine Without Aura:

41
Brain, Pituitary, Bone, Cortex, Monocytes, Occipital Lobe, Heart

Publications for Migraine Without Aura

Articles related to Migraine Without Aura:

(show top 50) (show all 227)
# Title Authors Year
1
Carbon monoxide inhalation induces headache but no migraine in patients with migraine without aura. ( 29540069 )
2018
2
Prospective memory is dysfunctional in migraine without aura. ( 29411639 )
2018
3
Evaluation of the effect of topical chamomile (Matricaria chamomilla L.) oleogel as pain relief in migraine without aura: a randomized, double-blind, placebo-controlled, crossover study. ( 29808331 )
2018
4
Right-to-left shunt may be prone to affect the white matter integrity of posterior circulation in migraine without aura. ( 29063453 )
2018
5
Visual Field Losses in Patients with Migraine without Aura and Tension-Type Headache. ( 28348627 )
2017
6
Altered thalamic connectivity during spontaneous attacks of migraine without aura: A resting-state fMRI study. ( 28853611 )
2017
7
Abnormal functional integration across core brain networks in migraine without aura. ( 28969471 )
2017
8
The power features of Masseter muscle activity in tension-type and migraine without aura headache during open-close clench cycles. ( 28775915 )
2017
9
Raven coloured progressive matrices in migraine without aura patients. ( 28527091 )
2017
10
RE: Six novel rare non-synonymous mutations for migraine without aura identified by exome sequencing. ( 29105529 )
2017
11
Correction to: Albury et al., RE: Six novel rare non-synonymous mutations for migraine without aura identified by exome sequencing. ( 29148276 )
2017
12
Cardiovascular risk factors and white matter hyperintensities in patients with migraine without aura. ( 29171645 )
2017
13
Functional Connectivity Differences in the Insular Sub-regions in Migraine without Aura: A Resting-State Functional Magnetic Resonance Imaging Study. ( 28701932 )
2017
14
Acupuncture modulates the abnormal brainstem activity in migraine without aura patients. ( 28580293 )
2017
15
Intact blood-brain barrier during spontaneous attacks of migraine without aura: a 3T DCE-MRI study. ( 28727225 )
2017
16
Response from Original Authors - RE: Six novel rare nonsynonymous mutations for migraine without aura identified by exome sequencing. ( 29037100 )
2017
17
Visual-spatial training efficacy in children affected by migraine without aura: a multicenter study. ( 28184165 )
2017
18
An Arterial Spin Labeling MRI Perfusion Study of Migraine without Aura Attacks. ( 28701991 )
2017
19
Headache Attributed to Fibrous Dysplasia of the Ethmoid Bone Mimicking Menstrual Migraine Without Aura. ( 27213743 )
2016
20
Grey zones in the diagnosis of adult migraine without aura based on the International Classification of Headache Disorders-III beta: exploring the covariates of possible migraine without aura. ( 25493966 )
2015
21
Endothelial Function in Patients with Migraine without Aura during the Interictal Period. ( 25789137 )
2015
22
P026. Pilot study on the use of coenzyme Q10 in a group of patients with episodic migraine without aura. ( 28132202 )
2015
23
Ultrasound-guided greater occipital nerve block: an efficient technique in chronic refractory migraine without aura? ( 25794201 )
2015
24
O005. Efficacy of oral supplement compared with amitriptyline in the prophylaxis of episodic tension-type headache and migraine without aura. ( 28132255 )
2015
25
The anterior insula shows heightened interictal intrinsic connectivity in migraine without aura. ( 25663219 )
2015
26
P019. Transcutaneous supraorbital neurostimulation in "de novo" patients with migraine without aura: the first Italian experience. ( 28132252 )
2015
27
Gene-based pleiotropy across migraine with aura and migraine without aura patient groups. ( 26660531 )
2015
28
Menstrual versus non-menstrual attacks of migraine without aura in women with and without menstrual migraine. ( 25754177 )
2015
29
O052. Migraine without aura and osteopathic medicine, a non-pharmacological approach to pain and quality of life: open pilot study. ( 28132208 )
2015
30
Elevated audiovisual temporal interaction in patients with migraine without aura. ( 24961903 )
2014
31
Thickening of the somatosensory cortex in migraine without aura. ( 24728304 )
2014
32
Sodium valproate in migraine without aura and medication overuse headache: a randomized controlled trial. ( 24862255 )
2014
33
Contraceptive-induced amenorrhoea leads to reduced migraine frequency in women with menstrual migraine without aura. ( 24884461 )
2014
34
Progestin-only contraception compared with extended combined oral contraceptive in women with migraine without aura: a retrospective pilot study. ( 25461375 )
2014
35
Migraine without aura is not associated with incomplete circle of Willis: a case-control study using high-resolution magnetic resonance angiography. ( 24886373 )
2014
36
Magnetic suppression of perceptual accuracy is not reduced in episodic migraine without aura. ( 25471445 )
2014
37
Cognitive dysfunction during migraine attacks: A study on migraine without aura. ( 25324500 )
2014
38
Progestogen-only contraceptive pill compared with combined oral contraceptive in the treatment of pain symptoms caused by endometriosis in patients with migraine without aura. ( 24965982 )
2014
39
A clinical interview versus prospective headache diaries in the diagnosis of menstrual migraine without aura. ( 25143553 )
2014
40
Association between promoter region of the uPAR (rs344781) gene polymorphism in genetic susceptibility to migraine without aura in three Iranian hospitals. ( 24731575 )
2014
41
Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study. ( 23578775 )
2013
42
Axonal loss of white matter in migraine without aura: a tract-based spatial statistics study. ( 23150889 )
2013
43
Hypersomnia in children affected by migraine without aura: a questionnaire-based case-control study. ( 23459616 )
2013
44
Heart rate variability in sleep-related migraine without aura. ( 23853566 )
2013
45
Self-concept evaluation and migraine without aura in childhood. ( 23950647 )
2013
46
Abnormal sensorimotor plasticity in migraine without aura patients. ( 23693159 )
2013
47
Alexithymia and its impact on quality of life in a group of Brazilian women with migraine without aura. ( 23565860 )
2013
48
Investigation of chemokine receptor CCR2V64Il gene polymorphism and migraine without aura in the Iranian population. ( 24453913 )
2013
49
Attachment styles in children affected by migraine without aura. ( 24124370 )
2013
50
Fatigue is increased in episodic migraine without aura patients. ( 23865916 )
2013

Variations for Migraine Without Aura

Expression for Migraine Without Aura

Search GEO for disease gene expression data for Migraine Without Aura.

Pathways for Migraine Without Aura

Pathways related to Migraine Without Aura according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.67 CACNA1A DRD2 DRD3 DRD4 SCN1A
2
Show member pathways
12.48 CACNA1A DRD2 DRD3 DRD4
3
Show member pathways
11.97 ATP1A2 DRD2 HTR1A
4 11.81 CACNA1A DRD2 DRD3 DRD4
5
Show member pathways
11.6 ATP1A2 CACNA1A SLC6A4
7 11.55 CACNA1A HTR1A SLC6A4
8
Show member pathways
11.44 DRD2 DRD3 DRD4
9
Show member pathways
10.98 DRD2 DRD3 DRD4 HTR1A
10 10.9 HTR1A SLC6A4
11 10.78 DRD2 DRD3

GO Terms for Migraine Without Aura

Cellular components related to Migraine Without Aura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 9.65 ASTN2 ATP1A2 CACNA1A DRD2 DRD3 DRD4
2 synapse GO:0045202 9.46 ATP1A2 CACNA1A MTHFR PHACTR1
3 integral component of plasma membrane GO:0005887 9.1 DRD2 DRD3 DRD4 HTR1A KCNK18 SLC6A4

Biological processes related to Migraine Without Aura according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.9 DRD2 DRD3 MTHFR SLC6A4
2 response to hypoxia GO:0001666 9.82 DRD2 MTHFR SLC6A4
3 social behavior GO:0035176 9.73 DRD3 DRD4 SLC6A4
4 visual learning GO:0008542 9.72 ATP1A2 DRD2 DRD3
5 response to morphine GO:0043278 9.67 DRD2 DRD3
6 membrane depolarization during action potential GO:0086010 9.66 CACNA1A SCN1A
7 behavioral fear response GO:0001662 9.66 DRD4 HTR1A
8 negative regulation of blood pressure GO:0045776 9.65 DRD2 DRD3
9 regulation of multicellular organism growth GO:0040014 9.65 DRD3 PRL
10 adult walking behavior GO:0007628 9.65 CACNA1A DRD2 SCN1A
11 regulation of dopamine secretion GO:0014059 9.64 DRD2 DRD3
12 synaptic transmission, dopaminergic GO:0001963 9.64 DRD2 DRD3
13 vasoconstriction GO:0042310 9.63 HTR1A SLC6A4
14 negative regulation of cytosolic calcium ion concentration GO:0051481 9.63 ATP1A2 DRD2
15 behavioral response to ethanol GO:0048149 9.62 DRD2 DRD4
16 positive regulation of renal sodium excretion GO:0035815 9.62 DRD2 DRD3
17 negative regulation of voltage-gated calcium channel activity GO:1901386 9.61 DRD2 DRD4
18 prepulse inhibition GO:0060134 9.61 DRD2 DRD3
19 response to amphetamine GO:0001975 9.61 DRD2 DRD3 DRD4
20 G-protein coupled receptor internalization GO:0002031 9.59 DRD2 DRD3
21 regulation of dopamine metabolic process GO:0042053 9.58 DRD4 HTR1A
22 neuron-neuron synaptic transmission GO:0007270 9.58 CACNA1A DRD2
23 arachidonic acid secretion GO:0050482 9.58 DRD2 DRD3 DRD4
24 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.57 DRD2 DRD3
25 musculoskeletal movement, spinal reflex action GO:0050883 9.54 CACNA1A DRD3
26 behavioral response to cocaine GO:0048148 9.54 DRD2 DRD3 DRD4
27 acid secretion GO:0046717 9.52 DRD2 DRD3
28 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.51 DRD2 DRD4
29 dopamine receptor signaling pathway GO:0007212 9.5 DRD2 DRD3 DRD4
30 negative regulation of dopamine receptor signaling pathway GO:0060160 9.49 DRD2 DRD3
31 regulation of locomotion involved in locomotory behavior GO:0090325 9.46 DRD2 DRD3
32 negative regulation of protein secretion GO:0050709 9.43 DRD2 DRD3 DRD4
33 dopamine metabolic process GO:0042417 9.33 DRD2 DRD3 DRD4
34 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.13 DRD2 DRD3 DRD4
35 response to histamine GO:0034776 8.8 DRD2 DRD3 DRD4

Molecular functions related to Migraine Without Aura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 obsolete signal transducer activity GO:0004871 9.62 DRD2 DRD3 DRD4 HTR1A
2 drug binding GO:0008144 9.56 ATP1A2 DRD2 DRD3 DRD4
3 dopamine binding GO:0035240 9.33 DRD2 DRD3 DRD4
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.13 DRD2 DRD3 DRD4
5 dopamine neurotransmitter receptor activity GO:0004952 8.8 DRD2 DRD3 DRD4

Sources for Migraine Without Aura

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....